Kamada Projects Strong Double-Digit Revenue and EBITDA Growth for 2026

summarizeSummary

Kamada Ltd. announced optimistic 2026 financial guidance, projecting double-digit revenue and adjusted EBITDA growth driven by organic expansion, while also affirming its 2025 targets.

check_boxKey Events

• 2026 Financial Guidance

  Kamada forecasts 2026 revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million.

• Double-Digit Organic Growth

  The 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA (mid-point basis), based solely on continued organic growth.

• 2025 Guidance Affirmed

  The company reaffirmed its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with approximately $75 million in year-end cash.

• Strategic Expansion

  Growth is expected from expanding the commercial product portfolio, launching biosimilars, extending distribution to the MENA region, and increasing plasma collection.

auto_awesomeAnalysis

Kamada Ltd. has provided robust financial guidance for 2026, forecasting significant double-digit increases in both revenues and adjusted EBITDA, driven by organic growth. This positive outlook, coupled with the affirmation of its 2025 financial targets and a healthy cash position, signals strong operational performance and strategic execution. The company's ability to project continued growth despite a reduction in GLASSIA royalty payments highlights the strength and diversification of its commercial product portfolio and plasma collection operations. Investors should view this guidance as a strong indicator of future profitability and market expansion.